CN107303006A - Improve the composition of menopause symptom or osteoporosis - Google Patents

Abstract

The present invention provides a composition for preventing women's menopausal symptoms and/or for improving, preventing or treating osteoporosis. The composition of the present invention has a rapid effect on preventing or improving women's menopausal symptoms, so it can effectively Use of hormone replacement therapy (Hormone replacement therapy; HRT) to prevent or improve menopausal symptoms in the past. In addition, unlike conventional therapeutic agents for climacteric symptoms in women, the composition of the present invention has no cytotoxicity, has few side effects, is safe, can be eaten as food, and can be used more effectively than conventional therapeutic agents for climacteric symptoms in females.

Description

Composition for improving menopausal symptoms or osteoporosis

technical field

The invention relates to a composition, which contains kudzu flower mixed extracts, and is used for preventing, improving or treating female menopausal symptoms and/or osteoporosis.

Background technique

Menopause in women is the genetically determined interruption of menstruation due to ovarian failure about 50 years after birth. Menopause, the loss of reproductive capacity, is a physiological change rather than a pathological phenomenon. At present, the average life expectancy of Korean women is 81.2 years (2011: Statistics Bureau), assuming that the average age of menopause of Korean women stipulated by the Korean Society of Obstetrics and Gynecology is 50 years old, it means that more than 1/3 of women's life is lived. In the state of female hormone depletion (Institute of Pharmaceutical Information, Kim Sung-chul).

Menopause causes the imbalance and decrease of female hormone secretion, leading to changes in the vascular system, musculoskeletal system, genitourinary system and cranial nerves. Simultaneous occurrence of various diseases and symptoms, namely: vasomotor symptoms and psychological symptoms, such as flushing, night sweats, insomnia, fatigue, depression, anxiety, concentration disorders, memory impairment; dyspareunia due to atrophy of the genitourinary system , frequent urination; loss of skin elasticity and breast sagging caused by collagen reduction; cardiovascular and musculoskeletal symptoms; dementia, etc. (non-patent document 1). Eighty-nine percent of women who undergo natural menopause experience at least one of the symptoms of menopause, and menopausal symptoms have also been reported to be more widespread.

Although menopausal symptoms vary from person to person, it is reported that the more menopausal symptoms experienced, the more serious, and the longer the time, the lower the quality of life of women (non-patent literature 2). Not only that, menopausal symptoms and physical Aging together is likely to lead to chronic diseases.

Treatments for menopause symptoms include hormone therapy, drug therapy, exercise therapy, or diet therapy. Among them, female hormone therapy, which is most used in medicine, can increase the risk of breast cancer, etc., and when used for a long time, it can increase the risk of uterine cancer, thrombovascular disease, gallbladder disease, and high blood pressure. Therefore, in order to replace estrogen therapy and other drug therapy, etc., studies on phytoestrogens (phytoestrogens) reported to have functions similar to estrogens have recently been increasing (Non-Patent Document 3).

The previous research on improving menopausal symptoms was to study the functional food containing Angelica, Chuanxiong, Radix Paeoniae Alba, Atractylodes Rhizoma Atractylodes Rhizome, White Poria, Red Ginseng and soybean extracts, which can improve menopausal symptoms (Patent Document 1); and, using A food containing astragalus, cassia seed, kudzu, and soybean extracts as main ingredients has an effect of improving women's menopausal symptoms (Patent Document 2).

Therefore, the inventors continue to research and develop natural materials that can comprehensively relieve menopausal symptoms and effectively improve osteoporosis caused by menopause, and finally complete the present invention.

technical literature

patent documents

Patent Document 1: Korean Laid-open Patent No. 10-2003-0048109

Patent Document 2: Korean Laid-open Patent No. 10-2006-0031203

non-patent literature

Non-Patent Document 1: J Korean Soc Menopause, 2012, 18:94-99

Non-Patent Document 2: Women health Noursing, Hyunmoonsa, 1997

Non-Patent Document 3: J East Asian Soc Dietary Life, 2006, 16(5), 533-541

Contents of the invention

The problem to be solved by the invention

The object of the present invention is to provide a composition that can effectively prevent, improve or treat the overall symptoms of female menopause and/or osteoporosis.

Technical solution to the problem

The present invention provides a composition for prevention, treatment or improvement, which includes: kudzu flower extract; and one or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel.

The above-mentioned composition may be a food composition, a pharmaceutical composition or a cosmetic material composition.

In addition, the present invention provides a health functional food containing the above-mentioned extract.

In addition, the present invention provides cosmetics, medicines and/or medical supplements comprising the above composition.

Invention effect

The composition of the present invention has the effect of rapidly preventing or improving women's menopausal symptoms and/or osteoporosis, therefore, it can be effectively used in the previous hormone replacement therapy (HRT) for preventing or improving menopausal symptoms. In addition, the composition of the present invention is different from conventional therapeutic agents for menopausal symptoms and osteoporosis in that it has no cytotoxicity, has few side effects, is safe, and can be eaten as food. Therapeutic agents can be used more effectively.

Description of drawings

Fig. 1 is a bar graph showing the activity of an extract of an embodiment of the present invention on estrogen receptor-positive human breast cancer cell lines.

Fig. 2 is a bar graph showing the promotion effect of the mixed extract of the present invention on the proliferation of osteoblasts according to an example of the present invention.

Fig. 3 is a bar graph showing the promoting effect of a mixed extract of an embodiment of the present invention on osteoblast differentiation.

Fig. 4 is a bar graph showing the inhibitory effect of a mixed extract of an example of the present invention on osteoclast proliferation.

detailed description

The invention relates to a composition for preventing, improving or treating menopausal symptoms, which includes: kudzu flower extract; and more than one extract selected from the group consisting of Fructus Aurantii and Tangerine Peel.

In addition, the present invention relates to a composition for preventing, improving or treating osteoporosis, which includes: kudzu flower extract; and more than one extract selected from the group consisting of Fructus Aurantii and Tangerine Peel.

Hereinafter, the composition of the present invention will be explained in more detail.

In one embodiment of the present invention, through experiments, it was confirmed that the breast cancer cell line (MCF-7cell line) was treated with the extract mixed with Pueraria japonica extract and Fructus aurantii or orange peel extract, and the cell viability was enhanced. As a result, menopausal symptoms were improved by taking the extract of the present invention (Experimental Examples 1 and 5). In addition, through experiments, it was confirmed that when the mixed extract of the present invention was used to treat osteoblast-like cells (MG-63cell), the proliferation of osteoblasts was promoted, and on the contrary, the proliferation of osteoclasts was inhibited (Experimental Example 2-2). 4).

Therefore, the mixed extract of the present invention can treat or improve menopausal symptoms and osteoporosis at the same time, so the composition of the present invention can be selected from the group consisting of: Pueraria japonica extract; Composition of more than one extract for preventing, treating or improving menopausal symptoms and/or osteoporosis.

As described above, the composition for preventing or improving menopausal symptoms and/or osteoporosis of the present invention includes mixed extracts. The above mixed extracts include: Pueraria japonica extract; and more than one extract selected from the group consisting of Fructus Aurantii and Tangerine Peel. More specifically, the above mixed extract may be a mixed extract of Pueraria japonica and Fructus Aurantii, a mixed extract of Pueraria japonica and tangerine peel, or a mixed extract of Pueraria japonica, Fructus aurantii and tangerine peel.

The mixed extract may contain 1 to 100 parts by weight of one or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel relative to 10 parts by weight of Pueraria japonica extract. Preferably, for 10 parts by weight of the kudzu flower extract, 5 to 50 parts by weight of one or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel can be included, and more preferably, the group consisting of Fructus Aurantii and Tangerine Peel can be included. 8 to 20 parts by weight of one or more extracts selected from In one embodiment of the present invention, it is confirmed that when the mixed extract contains kudzu flower and citrus aurantium extract or contains kudzu flower and tangerine peel extract, it has better improvement or prevention of female menopausal symptoms and osteoporosis than a single extract effect of the disease.

The "Puerariae Flos (Puerariae Flos)" of the present invention is the flower of the perennial herb Pueraria lobata belonging to the family Leguminosae, and is a traditional Chinese medicine widely used in clinical medicine. Also known as Pueraria japonica. Kudzu flower contains various compounds belonging to isoflavones. The kudzu flower mentioned above may be an unbloomed flower bud.

"Citri Fructus Aurantii" of the present invention is the fruit of plants Citrus aurantium, Citrus natsudaidai, or cultivars thereof belonging to the family Rutaceae. Preference may be given to immature fruit. Various compounds belonging to flavanone and flavonoid have been isolated as main components, and are reported to be effective in anti-oxidation and anti-inflammation. Specific examples of Citrus aurantium include: Aurantium acre, Aurantium bigarella, Aurantium corniculatum, Aurantium corniculatum, Aurantium coronatum, Aurantium distortum, Aurantium humile, Aurantium myrtifolium, Aurantium orientale, Aurantium Silvestre, Aurantium buritis sinense, Aurantium variitis variegatum, Aurantium haracegarus, Aurantium , Citrus amara, Citrus aurata, Citrus benikoji, Citrus bigaradia, Citrus calot, Citrus canaliculata, Citrus changshan-huyou, Citrus communis, Citrus dulcimedulla, Citrus dulcis, Citrus florida, Citrus funadoko, Citrus fusca, Citrus glaberrima, Citrus humilia ，Citrus iyo，Citrus karna，Citrus keraji，Citruskotokan，Citrus medioglobosa，Citrus mitsuharu，Citrus myrtifolia，Citrusnatsudaidai，Citrus omikanto，Citrus pseudogulgul，Citrus reshni，Citrusrokugatsu，Citrus rumphii，Citrus sinograndis，Citrus subcompressa，Citrussulcata，Citrus taiwanica，Citrus tangelo , Citrus tengu, Citrus tosa-asahi, Citrus runcate, Citrus vulgaris, Citrus yatsushiro, Citrus yuge-hyokan, but not limited thereto.

Chenpi (Citri Pericarpium) is the pericarp of Citrus unshiu Markovich of Rutaceae or the fruit of related plants. Alternatively, it may be the peel of the fruit of Citrus reticulata Blanco and cultivars thereof. Bitter in the mouth, pungent, warm in nature. It is used for vomiting, nausea and indigestion caused by spleen and stomach deficiency.

Pueraria japonica, Fructus aurantii or tangerine peel of the present invention can be purchased from commercial sales, and can also be cultivated or wildly extracted. In addition, the above-mentioned kudzu flower, citrus aurantii or tangerine peel includes all dried and pulverized forms regardless of the form.

The "extract" of the present invention can be extracted by treating an extraction object such as a plant body with an extraction solvent, or can be produced by fractional distillation by adding a fractionation solvent to the extract produced as an extraction solvent.

The above-mentioned extracts or fractions include: dilutions or concentrates of the above-mentioned extracts; dried products obtained by drying the above-mentioned extracts; partially refined products of the above-mentioned extracts, refined products or mixtures thereof, including the extract itself and the use of the extract All dosage forms available. Specifically, after the extract of the present invention is extracted, it can be made into dry powder for use. In addition, after performing the extraction or fractionation process, the solvent can be concentrated or removed by performing a vacuum filtration process or additionally performing concentration and/or freeze-drying. The extract obtained above can be kept in a deep freezer until use.

The extraction objects used for the extract of the present invention include all natural, hybrid or variant plants and cultures and cultures utilizing cell tissues.

The type of the above-mentioned extraction solvent is not particularly limited, and any solvent disclosed in the technical field of the present invention that can obtain an extract having the objective effect of the present invention can be used. Specifically, one or more types selected from the group consisting of water and organic solvents may be used. As the organic solvent, one or more solvents selected from the group consisting of alcohols having 1 to 5 carbon atoms such as methanol and ethanol, ethyl acetate, acetone, and chloroform can be used.

Water can be preferably used as the above-mentioned extraction solvent. In a specific embodiment, using purified water to extract the mixed extract of pueraria japonica and Fructus aurantii or tangerine peel, it was confirmed that the degree of menopausal symptoms was improved, and it was found that the cell activity, osteoblast differentiation and proliferation ability of the above-mentioned mixed extract treatment were enhanced, confirming that Menopausal symptoms improved in the experimental group who absorbed the mixed extract.

The partitioning solvent mentioned above can be water, butanol, ethyl acetate, diethyl ether, chloroform, benzene, hexane, methylene chloride or a mixture thereof. The above-mentioned fraction is the extract produced by the above-mentioned extraction method, specifically, it may be a fraction obtained through a fractionation process through an auxiliary extraction liquid. As the above-mentioned fractionation process, for example, after sequentially adding hexane, chloroform, ethyl acetate, butanol and water to the co-extraction solution, the hexane fraction, chloroform fraction, acetic acid Process completion for ethyl ester fraction, butanol fraction and water fraction.

The method for producing the extract of the present invention is not particularly limited, and it can be extracted by a method commonly used in the technical field of the present invention. The above-mentioned extraction method is not limited, for example, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, etc., one of which may be used alone or two or more methods may be used simultaneously. In addition, in order to obtain a high-purity extract, the same method can be used to extract more than once.

The term "menopausal symptoms" in the present invention is a generic term for symptoms and diseases that women exhibit before and after menopause due to decreased secretion of estrogen due to ovarian aging and the like. Also known as "menopausal syndrome" or "menopausal symptoms." Symptoms of menopause or menopause are, for example, flushing, sweating, nervousness, depression, dizziness, fatigue, joint pain, muscle pain, headache, palpitation, formication, sweating during sleep, insomnia, dry skin, Vaginal dryness, vaginal atrophy, lower urethral atrophy, dyspareunia, vaginitis, cystitis, dysuria, urgency, concentration disorder, memory impairment, anxiety, nervousness, memory loss, dry skin, joint pain or osteoporosis, etc. , but not limited to this. In addition, cardiovascular system abnormalities such as heart disease, high blood pressure, and stroke may also be one of the symptoms of menopause.

"Osteoporosis" in the present invention refers to a state in which bone strength is weakened and fractures are likely to increase, and the cause may be genetic factors, early menopause, drugs, smoking, or the like. Therefore, it may also be 'menopausal osteoporosis' caused by decreased hormone secretion such as menopause in women. Menopausal osteoporosis refers to the symptoms of osteoporosis caused by the decrease of hormone secretion in women during menopause, resulting in the damage of osteoblasts and tissues related to bone formation and the imbalance of osteoclasts related to resorption.

The "prevention" of the present invention refers to all actions of inhibiting or delaying the target symptoms after injection of the composition of the present invention.

"Treatment" in the present invention refers to all actions to improve or disappear the target symptom or disease after injection of the composition of the present invention.

"Improvement" in the present invention refers to all behaviors in which the target symptoms are improved or become more favorable after injection of the composition of the present invention.

The content of the extract contained in the composition of the present invention can be contained in an effective dose. The above term "effective dose" refers to the amount of the extract that can inhibit, delay or improve the symptoms of menopause or osteoporosis, or promote the differentiation and proliferation of osteoblasts.

The content of the above-mentioned mixed extract contained in the above-mentioned composition may contain various contents if there is prevention, improvement or treatment of menopausal symptoms or osteoporosis. Specifically, 0.001 to 30% by weight of kudzu flower extract, 0.001 to 30% by weight of Citrus aurantium extract, and 0.001 to 30% by weight of tangerine peel extract may be included with respect to the total amount of the composition. When the contained active ingredients are less than the minimum content, it may not be effective in preventing, treating or improving female menopausal symptoms or osteoporosis; when the contained active ingredients exceed the maximum content, the physical properties, color and The characteristic fragrance may affect the product.

In addition, according to an embodiment of the present invention, the above composition may contain 1 mg-1000 mg, preferably 5 mg-500 g, and more preferably 10 mg-300 g in 1 kg of the extract of the present invention.

The composition of the present invention may be a food composition for preventing or improving menopausal symptoms or osteoporosis.

In addition, the present invention provides a food containing the above composition for preventing or improving menopausal symptoms or osteoporosis.

Pueraria japonica, citrus aurantii and tangerine peel contained in the food composition of the present invention are natural substances, their stability has been proved in long-term use, and they can be ingested in the state of food that is generally ingested. Therefore, it can be expected to prevent or improve menopause. Symptoms or osteoporosis, play highly effective.

According to a specific embodiment, through experiments, it was confirmed that a group of subjects had the effect of improving menopausal symptoms after taking the soft capsules containing the kudzu flower and the extracts of Citrus aurantii or tangerine peel for a period of time.

The above-mentioned "food" refers to natural or processed products containing one or more nutrients. Preferably, it refers to an edible state made through a certain process. In addition, generally, health functional foods, functional foods, and beverages all contain food additives and beverage additives.

The above-mentioned foods include all foods in a general sense. For example, the food mentioned above may be various foods, beverages, chewing gum, tea, multivitamins, health functional food and the like. Moreover, in the present invention, foods also include special nutritional foods (for example, prepared milk, infant food, etc.), processed meat products, fish products, tofu, jelly (jellied food), noodles (for example, ramen noodles, Noodles, etc.), health supplements, seasoning foods (e.g., soy sauce, soybean paste, chili sauce, mixed sauce, etc.), sauces, biscuits (e.g., desserts), processed dairy products (e.g., fermented milk, cheese etc.), other processed foods, pickles, pickled foods (e.g. pickles, sauces, etc.), beverages (e.g. fruit and vegetable drinks, soybean milk, fermented beverages, etc.), seasonings (e.g. ramen soup, etc. ), but not limited to this.

The above-mentioned foods, functional foods, health functional foods, beverages, food additives and beverage additives can be manufactured by conventional manufacturing methods.

The "health functional food" of the present invention refers to a food group that adds value to the food through physical, biological, bioengineering methods, etc., so that the function of the food can be expressed in a specific purpose, or, Refers to the food that is designed and processed to fully express the body regulation functions of the food composition related to the regulation of the rhythm of the defense of the organism, disease prevention and recovery, etc. in the organism. Compared with general food, it has the effect of actively maintaining and improving health, and health supplement food (health supplement food) is a food for the purpose of supplementing health. The terms functional food, health food, and health supplement food can be mixed according to the situation. The above-mentioned functional food (functional food) is the same term as food for special health use (FoSHU), which refers to processed food that is not only effective in nutrition supply but also effective in regulating human body functions, and has high-efficiency medical and medical effects. The "functionality" of the present invention refers to the structure and function of the human body, which can regulate the health care effects such as nutritional elements and physiological effects, so as to obtain effective effects. The functional food of the present invention can be manufactured by methods commonly used in the art, and when manufactured by the above methods, it can be manufactured by adding commonly added raw materials and components. The composition for food of the present invention can be made into dosage forms in various forms. Unlike general medicines, food is used as a raw material. Therefore, it has the advantages of no side effects when taken for a long time, good portability, and is easy to be used as a promotion prevention or improvement of menopause. Aids absorption of symptoms or osteoporotic effects.

Specifically, the above-mentioned health functional food is that the extract of the present invention or its fractions are added to food materials such as beverages, teas, spices, chewing gum, biscuits, etc., or added to capsules, powders, suspensions, etc. Foods such as cloudy liquids mean that when ingested, they can bring specific health effects. However, unlike medicines, they have the advantage of no side effects when taken for a long time because they are made of food.

In the health functional food of the present invention, the above composition may contain 0.001-70 wt%, preferably 0.01-50 wt% or 0.1-30 wt%, in the total wt% of the health functional food.

The above-mentioned foods may contain food supplementary additives that are allowed to be added in food science, and may further include suitable carriers, excipients, and diluents that are usually used in the manufacture of health-care functional foods.

The above-mentioned composition may contain additional components generally used in food compositions to improve smell, taste, visual appearance, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, hydrochloric acid (niacin), biotin (biotin), folate (folate), pantothenic acid (panthotenic acid) and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr) may be contained. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be contained.

The above composition may contain preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleach powder and high-grade bleach powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA ), butylated hydroxytoluene (BHT), etc.), coloring agents (tar pigment, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (monosodium glutamate (MSG) glutamic acid sodium, etc.), sweeteners (sweetener, cyclamate, saccharin, sodium, etc.), flavors (vanilla, lactones), bulking agents (alum, D-potassium hydrogen tartrate, etc.), enhancers, emulsifiers, thickeners food additives (paste), coating agent, gum base, foam suppressor, solvent, improver, etc. The above-mentioned additives can be selected and used in appropriate amounts according to the type of food.

The composition containing the extract or its fractions of the present invention may directly contain the extract or its fractions, or may contain other foods or food ingredients at the same time, and may contain an appropriate amount according to a common method. The mixing amount of active ingredients can be determined according to the purpose of use (prevention, health or treatment). Usually, the food composition of the present invention is added in an amount of not more than 30 parts by weight of the raw material, preferably not more than 20 parts by weight of the raw material, when producing food or drink. However, in the case of long-term intake for the purpose of health and sanitation, the amount lower than the above-mentioned content may be included, and the amount of the active ingredient may be used in a larger amount than the above-mentioned range because there is no problem in terms of safety.

The composition of the present invention can also be used, for example, as a health drink composition.

"Beverage" in the present invention refers to the general term of substances to be drunk for thirst quenching or taste, including health functional drinks.

The beverage mentioned above is not particularly limited to other components except for the extract of the present invention as an essential component, and may contain other components such as various flavoring agents and natural carbohydrates similar to ordinary beverages.

The aforementioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugars such as xylitol, sorbitol, and erythritol. Alcohol etc. The above-mentioned flavoring agent may be a natural flavoring agent such as thaumatin, rebaudioside-A (Rebaudioside-A) or stevia extract of glycyrrhizic acid, or a synthetic flavoring agent such as essence or aspartame.

The amount of the natural carbohydrate added is usually about 1 g to 20 g, preferably 5 g to 12 g, per 100 ml of the food composition of the present invention, but is not limited thereto. In addition, the composition of the present invention may contain fruit pulp used for the production of natural fruit juices, fruit juice drinks, and vegetable drinks.

In addition to the above, the food composition of the present invention may contain various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), Pectinic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents for carbonated drinks, etc. Although the ratio of the above-mentioned additives is not critical, it is selected within the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The above-mentioned "health functional beverage" refers to a beverage group that has added value to the beverage through physical, biological, bioengineering methods, etc., so that the functional effect of the beverage can be expressed for a specific purpose, or it is Refers to beverages that are designed and processed to fully express the body regulation functions of the beverage components related to the regulation of organism defense rhythm, disease prevention and recovery, etc. in the organism.

The above-mentioned health functional drink contains the extract of the present invention as an essential component, and other components are not particularly limited, and may contain other components such as various flavoring agents or natural carbohydrates that are the same as common beverages.

The above-mentioned foods may also contain food additives. There are no other regulations on whether they are suitable as food additives. It is necessary to determine the specifications and standards of the corresponding categories through the general rules of the Food Additives Code and general experimental methods approved by the Department of Food and Drug Safety.

In addition, the composition according to the present invention may be a pharmaceutical composition containing mixed extracts useful for preventing or treating menopausal symptoms or osteoporosis.

In addition, the present invention relates to pharmaceuticals or pharmaceutical supplements, which include the above-mentioned pharmaceutical composition.

According to one embodiment, it has been confirmed through experiments that the mixed extract of the present invention is used to treat breast cancer cell line (MCF-7 cell line), and the cell activity is enhanced, and the extract of the present invention is directly taken by using the Cooperman index, and the result improves Climacteric symptoms (Experimental Example 1 and Experimental Example 5) were eliminated. In addition, it was confirmed through experiments that when osteoblast-like cells (MG-63 cells) were treated with the mixed extract of the present invention, the proliferation of osteoblasts was promoted, and on the contrary, the proliferation of osteoclasts was inhibited (Experimental Examples 2-4) .

The above-mentioned "pharmaceutical composition" refers to a composition used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of animals including humans.

The content of the extract of the present invention in the above composition may be an effective amount for preventing, improving or treating menopausal symptoms or osteoporosis. Specifically, 0.001-30% by weight of kudzu flower extract, 0.001-30% by weight of Citrus aurantium extract and 0.001-30% by weight of tangerine peel extract may be included for the whole composition. When the contained active ingredients are less than the minimum content, they may not be effective in preventing, treating or improving female menopausal symptoms or osteoporosis; when the contained active ingredients exceed the maximum content, the physical properties, color and The characteristic fragrance can affect the product.

In addition, the pharmaceutical composition of the present invention can be used alone or in combination with other active pharmaceutical ingredients effective in preventing or treating menopausal symptoms and/or osteoporosis.

The composition of the present invention can be administered to an individual in a pharmaceutically effective dose. The above-mentioned pharmaceutically effective dose refers to the acceptable reasonable benefit/risk ratio in medical treatment, which can fully treat the disease without causing side effects. The effective dosage standard can be based on the patient's health status, disease type, severity, The activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the release ratio, the course of treatment, the factors involved in the combination or simultaneous use of drugs, and other well-known factors in the medical field. Specifically, per 1 kg of body weight of the subject to be administered, usually 0.01 mg to 5000 mg per day, can be administered once or more times a day at certain intervals according to the judgment of a doctor or pharmacist, but is not limited thereto.

The above-mentioned composition can be administered to mammals including rats, mice, domestic animals, and humans through various routes such as non-oral, oral, etc., and all modes of administration can be expected, for example, oral, rectal or Administration is by intravenous, intramuscular, subcutaneous, intrauterine, or intracerebroventricular injection.

The pharmaceutical composition of the present invention may contain the above-mentioned extract alone as an active ingredient, and may also contain pharmaceutically acceptable carriers, excipients, diluents and/or auxiliary components according to the dosage form, method of use and purpose of use.

More specifically, in addition to the above active ingredients, nutrients, vitamins, electrolytes, flavoring agents, colorants, enhancers (enhancer), pectic acid and its salts, alginic acid and its salts, organic acids, protective Gum thickener, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent for carbonated drinks, etc.

The above-mentioned "pharmaceutically acceptable" means that it is physiologically acceptable and generally does not cause allergic reactions such as gastrointestinal dysfunction, dizziness, or similar reactions when administered to animals, preferably humans.

Examples of the above-mentioned pharmaceutically acceptable carrier, excipient or diluent include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch , Gum Arabic, Alginate, Gelatin, Calcium Phosphate, Calcium Silicate, Cellulose, Methylcellulose, Microcrystalline Cellulose, Polyvinylpyrrolidone, Water, Methylhydroxybenzoate, Propylhydroxybenzoate , talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, dextrin, calcium carbonate, propylene glycol, liquid paraffin and physiological saline, but not limited thereto, usually Carriers, excipients or diluents can be used.

The above-mentioned components may be added to the above-mentioned extract as an active ingredient singly or in combination.

The dosage form of the above-mentioned pharmaceutical composition can vary depending on the method of use, and can be formulated using methods known in the art to which the present invention pertains so as to provide rapid, sustained or delayed release of the active ingredient after administration to mammals. As examples of the above-mentioned dosage forms, there may be mentioned selected from ointments, creams, tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, aqueous solutions, non-aqueous solvents, suspensions, Dosage forms in the group consisting of formulations and emulsions.

For the above dosage forms, excipients may also be included, for example, conventional fillers, bulking agents, binders, disintegrants, surfactants, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, Preservatives, sweeteners, fragrances or preservatives, etc.

Generally, solid preparations for oral administration include tablets (TABLETS), tablets, soft or hard capsules (CAPSULES), pills (PILLS), powders (POWDERS) and granules (GRANULES), etc. The preparation can be prepared by mixing more than one excipient, for example, mixing starch, calcium carbonate, sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.

In addition, liquid preparations for oral administration include suspensions (SUSTESIONS), oral solutions, emulsions (EMULSIONS) and syrups (SYRUPS), etc., in addition to water or liquid paraffin as a simple diluent commonly used, Various excipients such as humectants, sweeteners, fragrances, preservatives and the like may also be included.

In the case of transdermal administration there are those suitable for the formation of body powders, lotions, suspensions, oils, sprays, ointments, greasy ointments, creams, gels, foams or solutions, and suitable for Carrier and/or excipient for transdermal drug delivery system (TTS: Transdermal therapeutic system). The topical pharmaceutical preparation of the present invention may be in the form of a semisolid dosage form, especially an ointment (solution ointment, suspension ointment), cream, gel or ointment. Mainly used in emulsions are: fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol; fatty acids such as palmitic acid or stearic acid, liquid or solid paraffin or ozokerite, liquid to solid waxes such as , isopropyl myristate; natural fats or partially synthetic fats, for example, coconut fatty acid triglycerides; hardened oils, for example, hydrogenated peanut oil or castor oil; or substances partially esterified of glycerol fatty acids, for example, monostearin glyceryl distearate or glyceryl distearate. As an excellent emulsifier, there are surfactants, including nonionic surfactants: fatty acid esters of polyhydric alcohols or their ethylene oxide adducts, for example, fatty acid polyglycerides or polyoxyethylene sorbitan fatty acids Esters; sorbitan fatty acid esters, for example, sorbitan oleate and/or sorbitan isostearate etc., isostearates, sterols, polyoxyethylene fatty alcohol ethers or fats Esters, anionic surfactants: alkali metal salts of fatty alcohol sulfonates, for example, sodium lauryl sulfate, sodium cetyl sulfate or sodium stearyl sulfate, these are usually in the presence of the aforementioned fatty alcohols, For example, in the presence of cetyl alcohol or stearyl alcohol. Among them, in particular, preparations for preventing the drying of the cream can be added, for example, polyhydric alcohols, namely glycerin, sorbitol, propylene glycol and/or polyethylene glycol, can be added to the water phase, or preservatives, fragrances etc. added to the aqueous phase.

The pharmaceutical preparation of the present invention can be an anhydrous ointment, suitable for topical use, and can contain paraffin wax that is liquid at body temperature, in particular, low-viscosity paraffin wax, or the above-mentioned pharmaceutical preparation can contain: the above-mentioned natural fat or part Synthetic fats, for example, coconut fatty acid triglycerides; hardened oils, for example, hydrogenated peanut oil or castor oil; substances of fatty acid partial esters of glycerol, for example, glyceryl monostearate and glyceryl distearate; silicones, such as , polymethylsiloxane, such as hexamethyldisiloxane or octamethyltrisiloxane. It may also contain, for example, fatty alcohols which are associated with aqueous creams and which enhance water absorption, as well as sterols, wool wax, other emulsifiers and/or other additives.

In the present invention, when formulating the above-mentioned pharmaceutical composition into a pharmaceutical, reference can be made to the content disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and the above-mentioned literature is regarded as a part of this specification.

The above-mentioned pharmaceutical composition may be a pharmaceutical supplement composition.

The term "medicine supplement" in the present invention refers to fiber, rubber products or similar products used for the purpose of treating, alleviating or preventing human or animal diseases; they have little effect on the human body, do not directly act on the human body, and are not Utensils or machines and similar thereto; articles used as prophylactics, corresponding to one of the preparations used for bactericidal, insecticidal and similar purposes, for the diagnosis, treatment, mitigation, treatment or prevention of man or animals of articles intended to be used for the purpose of treating diseases, other than appliances, machines or devices; and, of articles used for the purpose of pharmacologically affecting the structure and function of humans or animals, except thing. Specifically, it may refer to skin external preparations or personal hygiene products, but is not limited thereto.

When the mixed extracts or fractions of the present invention are added to pharmaceutical supplements for the purpose of preventing or treating menopausal symptoms or osteoporosis, the above-mentioned extracts or fractions can be added directly, or used simultaneously with other pharmaceutical supplements , can be appropriately used according to the commonly used method. The compounding quantity of an active ingredient can be suitably determined according to the purpose of use.

The aforementioned external preparations for skin are not particularly limited to the following forms, and can be used in the form of ointments, emulsions, sprays, ointments, creams, powders, suspensions, gels, or gels. The above-mentioned personal hygiene products are not particularly limited to the following products, which can be soap, cosmetics, wet wipes, toilet paper, shampoo, moisturizer, face cream, toothpaste, lipstick, perfume, makeup, foundation cream, blush, mascara, Eyeshadow, sunscreen lotion, hair care products, air fragrance gel or cleansing gel. In addition, the pharmaceutical auxiliary composition of the present invention also includes, for example, disinfectant cleaners, shower gels, wet wipes, soaps, hand sanitizers, masks or ointments.

In addition, for improvement, alleviation, treatment or prevention, the pharmaceutical composition of the present invention can be used alone, or the pharmaceutical composition can be used in combination with surgery, hormone therapy, drug therapy and methods using biological response regulators.

The present invention provides a method for preventing or treating menopausal symptoms or osteoporosis, comprising administering to an individual a pharmaceutically effective amount for preventing or treating menopausal symptoms or osteoporosis.

The terms "menopausal symptoms", "menopausal osteoporosis", "prevention", "treatment" and "administration" in the present invention are as described above.

The dosage, frequency and route of administration are as described above.

The term "individual" in the present invention refers to monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, All animals such as mice, mice, rabbits or guinea pigs can effectively prevent or treat the above-mentioned diseases by administering the composition of the present invention to individuals.

In addition, the above-mentioned composition according to the present invention may be a cosmetic material composition.

The above-mentioned cosmetic material composition can be used to prevent or improve menopausal symptoms or osteoporosis. Specifically, it may be a composition for improving or preventing symptoms such as dry skin or flushing of the face due to menopause.

The "menopausal symptoms", "menopausal osteoporosis", "improvement" and "prevention" of the present invention are as described above.

The effective dose of the above-mentioned extract contained in the composition of the present invention may vary depending on the form of the composition, the method of applying the above-mentioned extract to the skin, and the time it remains on the skin.

For example, when the above-mentioned composition is produced as a pharmaceutical for dermatological treatment, it may contain a higher concentration of the extract than when it is produced as a cosmetic for daily application to the skin. In addition, in the case of productization in the form of cosmetics, in the case of wash-off cosmetics such as makeup removers and cleansers in which the active ingredients stay on the skin for a short period of time, the extract may be contained at a relatively high concentration. Conversely, in the case of leave-on cosmetics such as lotion, lotion, cream, essence, etc., in which active ingredients stay on the skin for a long time, the extract may be contained at a lower concentration than rinse-off cosmetics .

In addition, the above composition can be used as an external preparation for skin.

The compositions described above can be used in any dosage form suitable for application to the epidermis. Specifically, for example, there may be solutions, suspensions, emulsions, ointments, gels, creams, lotions, powders, soaps, detergents containing surfactants, oils, foundation creams, lotions, cosmetics, etc. Dosage forms in the group consisting of ointment, spray, mask, sunscreen, barrier cream, powder, makeup remover and cleanser, but are not limited to the above specific examples.

For ease of use and handling, the extract-containing cosmetic material composition of the present invention may also include cosmetically acceptable carriers, diluents, auxiliary agents, colorants, stabilizers, flavoring agents, surfactants, oils , moisturizers, alcohols, thickeners, antioxidants, pH regulators, sunscreens, etc., when used as skin external compositions, can also be liquid, milk, cream, ointment, stick, mask, paste, powder etc. can be used in any dosage form applicable to the epidermis. In addition, one kind or two or more kinds thereof may be contained.

When the above-mentioned cosmetic material composition is formulated into cosmetics, it may contain known skin-acceptable excipients that act as carriers of active ingredients. For details, refer to International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association , Inc., Washington, 1995. The above-mentioned documents are made a part of this specification.

In addition, the present invention relates to a cosmetic comprising a mixed extract as an active ingredient thereof.

The above-mentioned cosmetics may be in any dosage form in the group consisting of lotion, essence, skin care lotion, lotion, cream, and mask.

For example, the above-mentioned cosmetics can be skin care water, toner, toner, astringent lotion, lotion, lotion, moisturizing lotion, nutrient lotion, massage cream, nutrient cream, moisturizing cream, hand cream, foundation cream, Essence, nutrient essence, mask, facial cleanser, cleanser, makeup remover, body milk, body wash, etc., but not limited thereto.

As mentioned above, unless otherwise specified in this specification, the numerical value described in this specification includes the range equivalent to it.

Hereinafter, in order to facilitate the understanding of the present invention, examples and the like will be described in detail. However, the embodiments according to the present invention may be changed into various other forms, and the scope of the present invention is not limited to the following embodiments. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.

Example

Production Example 1: Production of extracts for in vitro evaluation

The extract used in the following examples is an ethanol extract, purchased from OBM RAP CO., LTD for use, by adding the raw material of the extract mixed with 100% alcohol, extracting at normal temperature, and filtering to remove impurities, so that After the solid powder is concentrated to 85%, it is used in in vitro cell experiments.

Production Example 2: Production of Soft Capsules for Clinical Evaluation of Cooperman Index

The production process of soft capsules used in clinical trials is mainly divided into the process of producing the main raw material (menopausal subject) and the process of producing soft capsules.

First, after adding 10 times the amount of purified water to the dry powder sample of kudzu flower as the main raw material, it was extracted at 80° C. for 6 hours using an extraction device. The filter paper with a diameter of 160 mm is used for filtration, the filtered extract is concentrated under reduced pressure, freeze-dried, and then a powdered extract is produced. Fructus aurantii and tangerine peel are also used to make extracts in the same way.

Afterwards, after mixing and stirring the climacteric raw material as the main raw material, soybean oil, beeswax, soybean lecithin, and D-α-tocopherol as excipients, the air bubbles were removed, and the contents of the soft capsule were prepared, and the contents of the soft capsule were prepared with purified water and Pigment, glycerin, modified starch, and carrageenan are stirred to make a capsule base, the contents are filled and molded into the capsule base by weight, and then dried to make a soft capsule. The specific contents of the soft capsules are as listed in Table 1 below.

Table 1

Raw material name Comparative example 1 Comparative example 2 Comparative example 3 Comparative example 4 Example 1 Example 2 kudzu flower extract - 20 - - 10 10 Citrus Fructus Extract - - 20 - 10 - Chenpi Extract - - - 20 - 10 Soybean oil 92.95 72.95 72.95 72.95 72.95 72.95 beeswax 5 5 5 5 5 5 Soy lecithin 2 2 2 2 2 2 D-alpha-tocopherol 0.05 0.05 0.05 0.05 0.05 0.05

Experimental example 1: Determination of MCF-7cell cell viability (Cell Viability)

The cell viability (Cell Viability) of the Fructus Fructus Fructus extract was measured for the MCF-7 cell line of the estrogen receptor-positive human breast cancer cell line. Analysis of CCK-8 using MCF-7 cells is an experimental method that can confirm the influence of naturally occurring female hormones in the sample on women. MCF-7 cells were cultured in a 96-well plate (96well plate) using DMEM medium added with 10% FBS. After culturing for 24 hours, the negative control group (no treatment group, control) and the positive control group (Estradiol treatment group, E2), Pueraria japonica extract, Citrus aurantium extract, tangerine peel extract were treated individually or mixed, and after 72 hours , Cell Viability was measured using CCK-8. Absorbance was measured at 450 nm after treatment with 10 µl of CCK-8 sample per 100 µl of medium for 1 hour. The result is shown in Figure 1.

As shown in Figure 1, the cell viability of the whole extract treatment group was higher than that of the no treatment group (negative control group), but it was confirmed that the mixture of kudzu flower and citrus aurantii or tangerine peel extract Cell Viability was significantly increased when treated with substances.

Experimental Example 2: Proliferation-promoting effect of osteoblasts

In order to confirm the osteoblast proliferation-promoting effect, CCK-8 analysis was performed on human osteoblast-like MG-63 cells.

As the experimental group, a negative control group (no treatment group, control) and a positive control group (Estradiol treatment group, E2), each individual extract treatment group (Kudzu flower extract, Citrus aurantii extract, tangerine peel extract) and mixed extraction were used as the experimental group. Experiments were carried out in the treatment groups (Kudzu flower + Citrus aurantium extract, Pueraria flower + Tangerine peel extract).

First, a uniform number of MG-63 cells were cultured in a 96-well plate (96wellplate) using EMEM medium added with 10% FBS. After culturing for 24 hours, the negative control group (no treatment group, control) and the positive treatment group (Estradiol treatment, E2), Pueraria japonica extract, Citrus aurantium extract, tangerine peel extract were treated separately with FBS-free EMEM medium, Mix kudzu flower and citrus aurantium at a ratio of 1:1, and mix kudzu flower and tangerine peel at a ratio of 1:1. After 48 hours of treatment, cell viability was measured using CCK-8. Absorbance was measured at 450 nm after treatment with 10 µl of CCK-8 sample per 100 µl of medium for 1 hour. The result is shown in Figure 2.

As shown in Figure 2, it was confirmed that when the mixed extract was treated, the proliferation effect of osteoblasts was more excellent than when the extract was treated alone. In comparison, the osteoblast proliferation effect is better.

Experimental example 3: Osteoblast differentiation promotion effect

In order to confirm the osteoblast differentiation-promoting effect of each extract, ALP activity was measured using human osteoblast-like MG-63 cells.

The setting of the experimental group was carried out in the same manner as in Experimental Example 3.

First, a uniform number of MG-63 cells were cultured in a 24-well plate (24wellplate) using DMEM medium supplemented with 10% FBS. After culturing for 24 hours, the medium was replaced with 10% activated carbon FBS medium containing phenol red, and the negative control group (no treatment group, control) and the positive treatment group (Estradiol treatment, E2), kudzu flower extract, trifoliate orange Shell extract, tangerine peel extract, kudzu flower and orange peel are mixed in 1:1, and kudzu flower and tangerine peel are mixed in 1:1. After culturing for 3 days, they were treated again with the same medium and the same concentration of extract, and the culture was continued for 3 days. To measure total ALP activity, use pNPP Alkaline Phosphatase Assay Kit (ANASPEC AS-72146) for analysis. The cells were washed twice with Assay buffer, and after adding 200 μl of Assay buffer containing Triton X-100, the plate was placed on ice for shaking incubation for 10 minutes. Move the cell suspension (Cell suspension) to a microcentrifuge (microcentrifuge tube), and centrifuge at 2500Xg at 4°C, put 50 μl of the supernatant and 50 μl of the pNPP substrate into a 96-well plate (96well plate) After reacting for 30 minutes, the absorbance was measured at 450 nm. The result is shown in Figure 3.

As shown in FIG. 3 , it was confirmed that the cells treated with the mixed extracts had a more effective effect of promoting the differentiation of osteoblasts than those treated alone.

Experimental Example 4: Effect of Inhibiting Osteoclast Proliferation

In order to confirm the inhibitory effect of each extract on osteoclast proliferation, Rat Primary Precursor Osteoclasts culture Kit After culturing osteoclasts, CCK-8 analysis was performed. First, after seeding a uniform number of cells in a 96-well plate (96well plate) with the medium attached to the kit, immediately treat the negative control group, positive control group, kudzu flower , Citrus aurantium, tangerine peel individual extracts and kudzu flower+citrus aurantium, kudzu flower+tangerine peel mixed extract. After the sample was treated for 72 hours, the cell viability (Cell Viability) was measured by CCK-8. Absorbance was measured at 450 nm after treatment with 10 µl of CCK-8 sample per 100 µl of medium for 1 hour. The result is shown in Figure 4.

As shown in FIG. 4 , it was confirmed that the cells treated with the mixed extracts had the effect of inhibiting the proliferation of osteoclasts more effectively than those treated with the extracts alone. Especially in the case of mixing the extracts, it was confirmed that the effect of inhibiting the proliferation of osteoclasts was significantly improved depending on the concentration.

Experimental Example 5: Evaluation of Climacteric Symptom Relief Effect

60 women with menopausal symptoms in their 40s and half to 50s were randomly assigned, and after taking 3 soft capsules a day based on Comparative Examples 1-4 and Experimental Examples 1-2 for 8 weeks, the improvement of menopausal symptoms was evaluated. degree.

Comparative example 1 is a group not taken, comparative example 2 is a group taken with kudzu flower extract alone, comparative example 3 is a group taken with a single extract of Citrus aurantii, comparative example 4 is a group taken with a single extract of tangerine peel, and embodiment 1 is a group taken with kudzu flower and The group taking the mixed extract of Fructus Fructus Fructus Aurantii, Example 2 is the group taking the mixed extract of Pueraria japonica and tangerine peel. In the extract-treated group, the content of the extracts (mixed extracts when the extracts were mixed) was set to 20% by weight of the entire composition.

The degree of improvement of menopausal symptoms after 8 weeks of ingestion was measured by Kupperman index. When the value before ingestion was regarded as 100, the relative value after ingestion is shown in Table 2.

Cooperman index (KI) used in the present invention is used as the climacteric index used in academic circles, is 11 kinds of symptoms (flushing, sweating, insomnia, nervousness, depression, dizziness, fatigue, arthralgia) that menopausal women can produce Pain and muscle pain, headache, palpitation, and vaginal dryness) are scored, multiplied by the weighted value of each item to obtain a score, and the score obtained by adding them together is used as the menopause score.

Table 2

As shown in the above Table 2, it was confirmed that the compositions of Example 1, in which kudzu flower and Fructus Fructus Fructus were mixed, and Example 2, in which kudzu flower and tangerine peel were mixed, were more effective in relieving menopausal symptoms than when the respective extracts were treated alone.

Production Example 3: Production of Tablets

table 3

Raw material name Manufacturing example 3-1 Manufacturing example 3-2 kudzu flower extract 10 10 Citrus Fructus Extract 10 - Chenpi Extract - 10 microcrystalline cellulose 76.5 76.5 silica 1 1 Magnesium stearate 1 1 Hydroxypropylmethylcellulose 0.5 0.5

Claims (17)

1. A food composition for preventing or improving menopausal symptoms, comprising: kudzu flower extract; and One or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel. 2. The food composition for preventing or improving menopausal symptoms according to claim 1, wherein, With respect to 10 parts by weight of kudzu flower extract, One or more extracts selected from the group consisting of Fructus Fructus Fructus Fructus and Tangerine Peel are included in an amount of 1 to 100 parts by weight. 3. The food composition for preventing or improving menopausal symptoms according to claim 1 or 2, wherein the above-mentioned extract is made of water, alcohols with 1 to 5 carbon atoms, ethyl acetate, acetone and three Extraction of one or more extraction solvents selected from the group consisting of methyl chloride. 4. The food composition for preventing or improving menopausal symptoms according to claim 1 or 2, further comprising one or more ingredients selected from the group consisting of soybean oil, beeswax, lecithin and vitamin E. 5. A pharmaceutical composition for preventing or treating menopausal symptoms, comprising: kudzu flower extract; and One or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel. 6. The pharmaceutical composition for preventing or treating menopausal symptoms according to claim 5, wherein, With respect to 10 parts by weight of kudzu flower extract, One or more extracts selected from the group consisting of Fructus Fructus Fructus Fructus and Tangerine Peel are included in an amount of 1 to 100 parts by weight. 7. The pharmaceutical composition for preventing or treating menopausal symptoms according to claim 5 or 6, wherein the above-mentioned extract is made of water, alcohols with 1 to 5 carbon atoms, ethyl acetate, acetone and three Extraction of one or more extraction solvents selected from the group consisting of methyl chloride. 8. A food composition for preventing or improving osteoporosis, comprising: kudzu flower extract; and One or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel. 9. The food composition for preventing or improving osteoporosis according to claim 8, wherein, With respect to 10 parts by weight of kudzu flower extract, One or more extracts selected from the group consisting of Fructus Fructus Fructus Fructus and Tangerine Peel are included in an amount of 1 to 100 parts by weight. 10. The food composition for preventing or improving osteoporosis according to claim 8 or 9, wherein the above-mentioned extract is made of water, an alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone and the extract of more than one extraction solvent selected from the group consisting of chloroform. 11. A pharmaceutical composition for preventing or treating osteoporosis, comprising: kudzu flower extract; and One or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel. 12. The pharmaceutical composition for preventing or treating osteoporosis according to claim 11, wherein, With respect to 10 parts by weight of kudzu flower extract, One or more extracts selected from the group consisting of Fructus Fructus Fructus Fructus and Tangerine Peel are included in an amount of 1 to 100 parts by weight. 13. The pharmaceutical composition for preventing or treating osteoporosis according to claim 11 or 12, wherein the above-mentioned extract is made of water, an alcohol with 1 to 5 carbon atoms, ethyl acetate, acetone and three Extraction of one or more extraction solvents selected from the group consisting of methyl chloride. 14. A cosmetic material composition for preventing or improving menopausal symptoms, comprising: kudzu flower extract; and One or more extracts selected from the group consisting of Fructus Aurantii and Tangerine Peel. 15. A cosmetic comprising the composition of claim 14. 16. A pharmaceutical or pharmaceutical supplement comprising the composition of any one of claims 1 to 14. 17. A health functional food comprising the composition according to any one of claims 1 to 13.